New startup ideas · Health and bio · Healthcare and bio
startup idea
Vialport
AI agents that run the vendor paperwork between pharma R&D and outsourced labs.
Vialport gives pharma and large biotech R&D operations teams a fleet of AI agents that handle the non-clinical work between a sponsor and its outsourced labs: sourcing quotes from CROs and CDMOs, chasing certificates of analysis, reconciling sample shipments and invoices, and keeping study logistics current across email, ERP and ELN.
- AI agent as a service
- Enterprise
- $100B+ market
- Platform others build on
- Global from day one
4/5
venture judge
4
similar startups, last 2 years (18 all-time)
97%
of 4 nearest real companies still alive
yes
2 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$1,200 · 5 weeks · 30 prospects
For about $1,200 in five weeks, prove that outsourcing managers at mid-size biotechs will pay $2,000 up front for a hand-run service that chases quotes and certificates of analysis from their CROs, before any agent exists.
1Focus group: who and where
The outsourcing manager, external manufacturing lead or CMC program manager at a US clinical-stage biotech of 50 to 500 employees who is personally sending follow-up emails to 3 or more CROs and CDMOs each week chasing overdue quotes, certificates of analysis and shipment confirmations
where to find 30 · LinkedIn Sales Navigator filtered to 'outsourcing manager', 'external manufacturing' and 'CMC program manager' at US Biotechnology companies with 51 to 500 employees; the BioProcess International Conference in Boston in September 2026 for in-person meetings; r/biotech and the Bits in Bio Slack for warm sourcing
2Sell first, build later
A one-quarter design-partner pilot sold before the agents exist: Vialport takes over quote chasing, CoA collection and shipment reconciliation for up to 3 named CROs or CDMOs, every request acknowledged in one business day and status current in a shared sheet, live within 10 business days of signature
the ask · $2,000 per quarter for the pilot workflow, or $75 per closed request for companies that prefer usage pricing
a real yes · A real yes is a paid $2,000 invoice or two consecutive weeks of paid per-request invoices; 'this would save us so much time', a forwarded request with no payment after the free tier, and an intro to procurement do not count
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Fifteen workflow discovery calls
$100 · 14 days
Book 15 calls through Sales Navigator outreach with a Loom video showing a mocked agent thread chasing a CoA across email and an ERP screen. On each call, map their current chase process, count their open requests, and ask them to forward one live overdue request for Vialport to close as a test.
keep going if · 6 of 15 forward a real open quote or CoA request within a week of the call
2. Concierge request-closing service
$300 · 21 days
For 3 companies, run the workflow entirely by hand behind a dedicated inbox: chase their named CROs and CDMOs for quotes, CoAs and shipment paperwork, log turnaround per vendor, deliver a weekly status sheet. First 5 requests free, then $75 per closed request, invoiced weekly through Stripe.
keep going if · 20 requests closed across 3 companies and at least 2 companies pay the per-request invoices without pushback
3. Paid pilot offer at BPI
$800 · 21 days
Mail a one-page offer to all 30 prospects and work the BioProcess International expo floor with it: a one-quarter pilot covering quote and CoA chasing against up to 3 named vendors, unlimited requests, $2,000 invoiced up front, live within 10 business days. One founder runs the booth-less meeting circuit with a printed offer sheet.
keep going if · 6 of 30 book a pilot scoping meeting and 3 receive the pilot invoice
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$2,000
per prospect, refundable
how · A paid design-partner pilot: $2,000 invoiced up front through Stripe on a one-page agreement signed by the head of R&D operations; the work is unregulated and touches no patient data, so it clears on a department card or a sub-$5,000 PO set up: Stripe Invoicing ↗
what it reserves · One of five design-partner slots, the $2,000 quarterly rate locked for year one, and their 3 named vendors onboarded first when the agent version ships
refund · Refunded in full if fewer than 10 requests are closed in the first 30 days
target · 3 paid pilots from 30 conversations within 42 days
Go: build it if
3 companies pay $2,000 up front and route 10+ live requests each in the first month: build the agent to replace the manual inbox
Kill: stop if
30 prospects reached and fewer than 4 forward a live request, or everyone uses the free tier and no one pays an invoice: the pain is real but not budget-worthy, stop
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
82
Idea Score, 0-100 · raw 49.9 x 1.64
Active
competition: more crowded than 47% of ideas · headwind x0.76
+1.2
government priorities, secondary (2 matching grants)
Trend
61
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)51
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
60
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain50
100x potential
71
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge75
- Market size axis100
- Moat axis100
- Neighbours still alive76
- Technologist judge0
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were vendor, paperwork, pharma, outsourced, labs, biotech, operations, fleet.
The idea in full
- What
- Vialport gives pharma and large biotech R&D operations teams a fleet of AI agents that handle the non-clinical work between a sponsor and its outsourced labs: sourcing quotes from CROs and CDMOs, chasing certificates of analysis, reconciling sample shipments and invoices, and keeping study logistics current across email, ERP and ELN. It sells as a per-workflow subscription with a small implementation fee, sits entirely outside GxP and touches no patient data. After the first year the agent actions are exposed as an API and skill format, so instrument vendors, CROs and internal IT teams publish their own connectors on top.
- Why now
- The radar shows the outsourcing layer itself becoming a software target inside one year: Harbor (yc X26) is an AI-native CRO for trial operations and AbInitio Bio (yc X26) is an intelligence layer for drug manufacturing, while the cluster added 126 new companies in the 2024 cohort alone against 1759 all-time, so buyers now expect agents rather than dashboards.
- Wedge: first customer and entry point
- One mid-size biotech's outsourcing manager, single workflow: chasing quotes and certificates of analysis from three named CROs, priced per closed request so the first agent pays for itself in one quarter.
- Path to 100x
- Outsourced pharma R&D and manufacturing spend clears $100B a year globally, and every dollar of it moves through quotes, shipments and reconciliations that no one owns today. Winner takes most because each completed workflow teaches the agents a vendor's real turnaround, pricing and document formats, and once outside parties publish connectors against that library the graph of sponsor-to-vendor interactions is not reproducible by a second entrant.
- Ceiling
- If the ten largest CROs each ship their own free sponsor portal, Vialport is squeezed into a thin integration tool worth a few hundred million.
- Closest real companies, as the generator saw them
- Harbor replaces the CRO itself and AbInitio Bio goes deep into manufacturing intelligence; Vialport stays neutral back-office plumbing between sponsor and any vendor, which is why competing CROs will connect to it. Panacea works the regulatory filing side, not vendor operations.
- Main risk
- Pharma procurement teams treat vendor paperwork as an ERP configuration problem and hand it to their existing SAP integrator instead of a startup.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
4/5
Capital-light agents on $100B+ outsourced R&D spend with a sponsor-to-vendor interaction graph that a second entrant cannot reproduce.
Bootstrapper
4/5
Unregulated back-office paperwork priced per closed request, capital-light, with an outsourcing manager who can sign a single-workflow pilot.
Operator
3/5
Chasing certificates of analysis is real and frequent, but no one owns that paperwork budget today, which is why procurement hands it to the SAP integrator.
Technologist
1/5
Chasing quotes and certificates of analysis over email and ERP is agent glue an SAP integrator or any CRO portal absorbs.
Risk
4/5
Sits outside GxP with no patient data, sells neutral plumbing to any vendor, and per-workflow pricing survives any single CRO changing terms.
trends
2/5
Buyers-now-expect-agents is the generic 2026 claim; vendor paperwork automation was equally true in 2023 and the agent cluster is already packed.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (vendor, paperwork, pharma, outsourced, labs, biotech, operations, fleet): 18 all-time, 4 from the last two years. Same matching as Idea Check.
Nomic is doing for proteins what Illumina has done for DNA
AIoT monitoring, workflow, and evidence systems for regulated labs.
The vendor-neutral coordination and translation layer for biomanufacturing data, connecting pharma sponsors and their manufacturing partners so AI can finally scale and deliver real value.
Robotic pitstops for self-driving cars
The Fastest Multimodal Inference OS
Making hard molecules for Pharma and Biotech
Battery Insurance for Commercial Electric Vehicles
Charging session management for fleet EVs.
AI-powered risk and compliance for financial institutions
Agency replaces traditional security and compliance headcount with AI.
The AI workforce for freight dispatch
India's fastest medicine delivery in just 30 minutes
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
2
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
- A Universal Platform for Ultrahigh-Throughput Biocatalyst Evolution With micro-Mass Spectrometryawardhigh relevance
NIH / NIGMS · SBIR phase II · $307K · posted 2025-08-01
- NSF PCL-Test Bed: Towards a General Platform for AI-Driven High-Throughput Reaction Discovery and Automationawardmedium relevance
National Science Foundation · PCL-Programmable Cloud Labs · $20M · posted 2026-07-21
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- AI agent as a service
- Path to 100x
- Platform others build on
- Market size
- $100B+ market
- Capital intensity
- Capital-light (software margins)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Integrations, no-code
- Go-to-market
- Founder-led sales
- Moat
- Data moat
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.